Please login to the form below

Not currently logged in
Email:
Password:

Glioblastoma market set for 'meteoric rise'

Sales of treatments for rare brain cancer predicted to reach $3.3bn by 2024

Brain cancer glioblastoma 

Sales of drugs to treat a rare and aggressive form of brain cancer are expected to see considerable growth over the next eight years, with Bristol-Myers Squibb's Opdivo tipped to lead the way.

The combined glioblastoma market for the US, UK, Spain, France, Germany, Italy and Japan will see a 'meteoric rise', expanding from $659m in 2014 to $3.3bn by 2024, according to research and consulting firm GlobalData.

Its analyst covering oncology and haematology Maxime Bourgognon said: “Although glioblastoma is a rare disease, such high levels of unmet need in the market have created ample opportunities for players with effective therapies. 

“However, developing drugs which effectively treat glioblastoma has proved exceedingly challenging to date, predominantly due to the presence of the blood-brain barrier, which prevents many drugs from entering the brain and attacking the tumour.”

GlobalData predicts that current pipeline drugs could offer a way through this, and says BMS' immunotherapy Opdivo (nivolumab) is “a particular contender to become the primary standard of care by 2024”.

First approved in 2014, BMS last year joined forces with Lilly for phase I and II studies of Opdivo and Lilly's galunisertib in advanced glioblastoma and other solid tumours.

There is also hope that Opdivo could treat patients resistant to Roche's Avastin (bevacizumab), and to that end BMS is running a phase III trial of Opdivo - on its own and in combination with BMS's own Yervoy (ipilimumab) versus Avastin.

Bourgognon added: “Immunotherapies have shown significant efficacy in other oncology indications, and as they affect the tumor microenvironment rather than directly targeting the tumour, they make attractive candidates for glioblastoma treatments.

“Currently, Avastin dominates the market, working by inhibiting angiogenesis and disrupting the blood-brain barrier, which in turn leads to tumor starvation. Patients refractory to the drug, however, have scant treatment options, and Opdivo addresses this.”

Of the seven major markets covered by GlobalData's report, the firm says Japan will see the most impressive relative growth, with sales expanding from $47m in 2014 to $268m million in 2024, driven by higher pricing for Opdivo.

Article by
Dominic Tyer

15th January 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
nitrogen

nitrogen is a strategic brand experience agency which blends science and imagination; delivering multi-channel communications that are both compelling and...

Latest intelligence

Acute leukaemia patients get new online information centre that will help them get the best possible care
A unique collaboration between some of the world's leading leukaemia experts and the patient community in the UK and across Europe has resulted in the development of a one-of-a-kind educational...
How to conduct a pharma content audit
A pharma content audit is essential for identifying whether your site delivers comprehensive, valuable information for the purpose of meeting the needs of your content marketing efforts....
14_ipad_lowres.jpg
Do your customers feel that you’re listening to them?
When answering to data, excellent digital communication can create much stronger relationships between reps and customers....

Infographics